Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179732 | 0.86 | KDM4E (0.52) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1180004 | 0.86 | CD74 (0.54) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL3496372 | 0.85 | HDAC8 (0.69) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL6193094 | 0.84 | PLA2G10 (0.57) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL1180094 | 0.83 | BCL2 (0.54) | HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL3109875 | 0.83 | HDAC6 (0.61) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL8685995 | 0.83 | HDAC8 (0.60) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL12404142 | 0.82 | HDAC8 (0.51) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL3506950 | 0.82 | PLAU (0.48) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL28580016 | 0.81 | HDAC8 (0.54) | HDAC1HDAC2HDAC10HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
| CN-1250542-C | 2-(1H-indol-3-yl)-2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2006-04-12 | — | — | CN | disclosed |
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| CN-1413205-A | 2- (1H-indol-3-yl) -2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2003-04-23 | — | — | CN | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | HDAC1 135/4885HDAC2 147/4885HDAC10 942/4885 |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | FLI1, API5, MAVS | HDAC1 1208/4885HDAC2 1679/4885HDAC10 2189/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC1 6/4885HDAC2 10/4885HDAC10 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.